DNA

Alvaria Launches Innovation Lab, Alvaria Horizons

Retrieved on: 
Thursday, April 25, 2024
Professional Services, Data Management, Technology, Data Analytics, Human Resources, Software, Abry, COVID, Thought, Machine learning, Blockchain, History, Intelligence, DNA, Automatic call distributor, ACD, Aspect, Management

Alvaria®, a leader in contact center infrastructure and workforce engagement software, launches Alvaria Horizons™, a lab dedicated to pioneering new ideas and building innovative technologies that redefine the future of work.

Key Points: 
  • Alvaria®, a leader in contact center infrastructure and workforce engagement software, launches Alvaria Horizons™, a lab dedicated to pioneering new ideas and building innovative technologies that redefine the future of work.
  • Their legacy of innovation and excellence make them a trusted partner for leaders across all industries, from commercial banks to airlines and beyond.
  • Alvaria Horizons’ first project redefines how the world’s leading companies use technology to create a new experience of work for their people.
  • “This type of dedication to innovation is hard to come by in this industry and we’re beyond excited to watch Alvaria embark on this journey with Horizons.

Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)

Retrieved on: 
Thursday, April 25, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Molecule, MSI, Werner syndrome, Roche, DNA, WRN, Therapy, DSM-IV codes, Microsatellite instability, Drug development, Drug discovery, Cancer, Development, Head, Pharmaceutical industry

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.

Key Points: 
  • Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.
  • The publication, “Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase,” by Kristen Baltgalvis et al, published jointly with our partner Roche, speaks to the chemical proteomic-enabled discovery of a clinical-stage, covalent allosteric inhibitor of Werner helicase (WRN), VVD-133214 (RO7589831), and further confirms Vividion’s approach to discovering and developing novel therapeutics.
  • “Vividion discovered covalent ligands targeting a novel allosteric pocket on WRN, a well- known but challenging therapeutic target in drug development.
  • The WRN molecule was identified under the collaboration agreement entered between Vividion and Roche in 2020.

UPROXX Studios Blazes Independent Path

Retrieved on: 
Wednesday, April 24, 2024
TV and Radio, Music, Technology, Licensing (Entertainment), General Entertainment, Entertainment, Communications, Social Media, Apps, Applications, Artificial Intelligence, Audio, Video, Investment, Radio, Social media, AI, Warner Music Group, WMX, Publishing, HipHopDX, Partnership, Communication, Freedom, Growth, WMG, FYI, DNA, Acquisition, Multimedia, Marketing, Advertising, Complex Networks, Creativity, Partner

This powerhouse independent company emerged from the strategic acquisition of Uproxx, HipHopDX, Dime Magazine, and other leading media assets from Warner Music Group (WMG).

Key Points: 
  • This powerhouse independent company emerged from the strategic acquisition of Uproxx, HipHopDX, Dime Magazine, and other leading media assets from Warner Music Group (WMG).
  • View the full release here: https://www.businesswire.com/news/home/20240424375244/en/
    The creation of UPROXX Studios also includes the exclusive license to represent WMG’s coveted YouTube inventory for all media sales in the United States.
  • The newly formed UPROXX Studios will integrate the power of will.i.am’s FYI AI technology and FYI radio into their operations.
  • This collaboration includes the creation of AI StoryLabs, a specialized unit within UPROXX Studios that harnesses advanced conversational AI to transform brand communication.

Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer

Retrieved on: 
Wednesday, April 24, 2024
Oncology, Medical Devices, Health, Hospitals, Clinical Trials, Biotechnology, Cancer, HNSCC, MRD, Recurrence, Doctor of Philosophy, Research, MSKCC, DNA, Patient, HPV, Head, Neoplasm, TTMV

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer.
  • The study will be led by Memorial Sloan Kettering Cancer Center (MSKCC), a top cancer treatment and research institution.
  • “This study will propose a novel intervention for patients with MRD+ HPV-driven head and neck cancer and will assess the ability of NavDx to identify MRD in these patients,” said Alan L. Ho, MD, PhD, Head and Neck Oncologist and Cellular Therapist, Memorial Sloan Kettering, and the primary principal investigator for the study.
  • We are grateful to the research team at Memorial Sloan Kettering Cancer Center for their collaboration and we look forward to presenting the results of this study when they are complete.”

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

T-Mobile Rolls Out Two New Internet Plans to Give Customers Enhanced Options for Home and On the Go

Retrieved on: 
Tuesday, April 23, 2024
5G, Telecommunications, Internet, Hardware, Consumer Electronics, Technology, Carriers and Services, Mobile, Wireless, Sale, AT&T, News, Safety, UN, Congestion, Verizon Communications, WPA3, Wi-Fi, Parent, TMUS, Camping, Internet service provider, DNA, Tax, HD, Multimedia, T-Mobile, Consumer electronics

Following another industry-leading year, T-Mobile is giving customers new plans that cater to different lifestyles, keeping them connected the way they want.

Key Points: 
  • Following another industry-leading year, T-Mobile is giving customers new plans that cater to different lifestyles, keeping them connected the way they want.
  • “T-Mobile is doing what we do best, listening to customers and offering new plans to meet their needs,” said Allan Samson, Chief Broadband Officer, T-Mobile.
  • Today 95% of adults in the U.S. are using the internet compared to just over 75% in 2010.
  • A recent study even found that T-Mobile 5G Home Internet customers are overall happier than traditional cable internet customers.

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Retrieved on: 
Tuesday, April 23, 2024
Retail, Health, Supermarket, Fitness & Nutrition, General Health, Pharmaceutical, Vitamins, Supplements, Sprouts, United, ChromaDex, Nobel Prize, Partnership, Research, Farmer, NAD, DNA, Science, Sprouts Farmers Market, DNA repair, Sprout, Dietary supplement

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut.
  • As one of the fastest-growing retailers in the United States, Sprouts Farmers Market now offers Tru Niagen to its health-conscious consumers in more than 400 locations across 23 states.
  • “We are privileged to have Sprouts as the first major grocery chain to carry Tru Niagen,” said Rob Fried, CEO of ChromaDex and Founder of Tru Niagen.
  • Sprouts Farmers Market is known for its curated selection of healthy groceries and is a go-to destination for wellness enthusiasts and those embarking on their health and wellness journeys.

Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform

Retrieved on: 
Tuesday, April 23, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Wellington Partners, Enzyme, University, Disorder, Gene editing, Seamless, Entrepreneurship, Disease, DNA, Therapy, Patient, Human genetics, Acquisition, Independent, Genome, Growth, Head, Pharmaceutical industry

Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies.

Key Points: 
  • Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies.
  • In addition, their combined experience will be instrumental in establishing Seamless Therapeutics’ Research and Development (R&D) activities in the US.
  • Early in vivo preclinical evidence has shown that Seamless’ programmable recombinases can precisely edit a 138 kilobase fragment through inversion.
  • “Seamless Therapeutics is at the forefront of the next wave of innovation in gene editing with its unique platform and comprehensive toolbox capable of programming recombinases.

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Monday, April 22, 2024
Research, Infectious Diseases, Neurology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, STAC, Neuron, Central nervous system disease, Dravet syndrome, Central nervous system, MD, Sangamo Therapeutics, Cell, AAV, Tauopathy, CNS, Engineering, DNA, Charcot–Marie–Tooth disease, Patient, Gene, Society, DSM-IV codes, Prion, Angelman syndrome, ALS, Genome, Capsid, Therapy, Powder metallurgy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.
  • Presentations will focus on the progression of Sangamo’s neurology-focused pre-clinical pipeline, including data supporting innovations in zinc finger epigenetic regulation, advances in AAV capsid engineering, and discovery of next-generation integrase technology.
  • These data will showcase a novel AAV capsid, STAC-BBB, that exhibited robust and widespread central nervous system transduction in cynomolgus macaques after intravenous delivery, as well as another novel AAV capsid, STAC-150, engineered to accelerate the discovery of potent and highly specific epigenetic regulators.
  • Sangamo will also present additional data from its AAV capsid engineering platform SIFTER and its efforts for integrase evolution and utilization.

Profluent Successfully Edits Human Genome with OpenCRISPR-1, the World’s First AI-Created and Open-Source Gene Editor

Retrieved on: 
Monday, April 22, 2024
Research, Technology, Genetics, Health Technology, Software, Pharmaceutical, Health, Data Management, Science, Artificial Intelligence, Sickle cell disease, CRISPR, Nature, AI, Gene editing, RNA, Disease, DNA, Patient, Gene, Genome, Medical device

Profluent, the AI-first protein design company, today debuted the OpenCRISPRTM initiative, releasing the world’s first open-source, AI-generated gene editor.

Key Points: 
  • Profluent, the AI-first protein design company, today debuted the OpenCRISPRTM initiative, releasing the world’s first open-source, AI-generated gene editor.
  • With this launch, Profluent demonstrates the first successful precision editing of the human genome with customizable gene editors designed from scratch with AI.
  • OpenCRISPR-1 is an AI-created gene editor, consisting of a Cas9-like protein and guide RNA, fully developed using Profluent’s large language models (LLMs).
  • “Attempting to edit human DNA with an AI-designed biological system was a scientific moonshot,” said Ali Madani, Profluent co-founder and Chief Executive Officer.